CDXS
Codexis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.44
+1.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 77.7M | 70.4M | 59.3M | 70.1M | 138.6M |
| Cost of Revenue | 12.7M | 9.3M | 16.3M | 12.8M | 38.0M |
| Gross Profit | 65.0M | 61.0M | 43.1M | 57.3M | 100.6M |
| Operating Expenses | |||||
| R&D Expense | 46.8M | 52.3M | 46.3M | 58.9M | 80.1M |
| SG&A Expense | 42.5M | 47.1M | 55.1M | 53.3M | 52.2M |
| General & Admin Expense | 10.9M | — | — | 53.0M | — |
| Selling & Marketing Expense | — | — | — | 300.0K | — |
| Other Expenses | — | — | 165.0K | 13.3M | 3.2M |
| Total Operating Expenses | 89.3M | 99.4M | 101.6M | 125.4M | 135.4M |
| Cost and Expenses | 101.9M | 108.7M | 117.9M | 138.2M | 173.5M |
| Operating Income (EBIT) | (24.3M) | (38.3M) | (58.5M) | (68.1M) | (34.9M) |
| Non-Operating | |||||
| Interest Income | 2.5M | 2.6M | 3.7M | 4.2M | 1.4M |
| Interest Expense | 1.3M | 4.8M | — | — | — |
| Net Interest Income | 1.2M | (2.2M) | 3.7M | 4.2M | 1.4M |
| Other Non-Op Income/Expense | (6.4M) | (5.6M) | (6.7M) | (8.1M) | 1.6M |
| Non-Operating Income (excl Interest) | 5.1M | 782.0K | (165.0K) | (13.3M) | (3.2M) |
| EBT (Pre-Tax Income) | (30.7M) | (43.9M) | (65.2M) | (76.2M) | (33.3M) |
| Income Tax Expense | 72.0K | 47.0K | 34.0K | 69.0K | 276.0K |
| Bottom Line | |||||
| Net Income | (30.7M) | (44.0M) | (65.3M) | (76.2M) | (33.6M) |
| Earnings from Cont. Ops | (30.7M) | (44.0M) | (65.3M) | (76.2M) | (33.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.7M) | (44.0M) | (65.3M) | (76.2M) | (33.6M) |
| Per Share | |||||
| Basic EPS | ($0.34) | ($0.50) | ($0.89) | ($1.12) | ($0.51) |
| Diluted EPS | ($0.34) | ($0.50) | ($0.89) | ($1.12) | ($0.51) |
| Revenue Per Share | $0.85 | $0.81 | $0.81 | $1.03 | $2.12 |
| Shares | |||||
| Basic Shares Outstanding | 91.1M | 87.1M | 73.4M | 68.1M | 65.3M |
| Diluted Shares Outstanding | 91.1M | 87.1M | 73.4M | 68.1M | 65.3M |
| Profitability Metrics | |||||
| EBITDA | (21.6M) | (33.9M) | (53.4M) | (49.3M) | (26.3M) |
| D&A | 7.7M | 5.2M | 4.9M | 5.5M | 5.4M |
| EBIT | (29.4M) | (39.1M) | (58.4M) | (54.8M) | (31.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026